Cytovation ASA
Latest round
- Series A
Last raised
- Jun 2023
Total raised
- $28M
Investors
- 2
About Cytovation ASA
Founded in 2015 and headquartered in Bergen, Norway, Cytovation ASA focuses on creating immunotherapy products for oncology. The firm has not undergone any significant changes in business strategy or structure since its inception.Cytovation specializes in innovative immunotherapy solutions, primarily developing its core product, CY-101, to treat cancer patients with ß-catenin driven tumors. Utilizing a unique peptide technology, CY-101 aims to trigger the immune system to specifically target and eliminate tumors.70 in 2023. The company generates revenue primarily through the sale of its immunotherapy product CY-101 to healthcare providers, including hospitals and oncology clinics. Given the complexity and high value of these treatments, Cytovation may engage in one-off sales or partnership agreements with treatment centers to facilitate ongoing patient care. The company is focused on expanding its market reach, specifically targeting new regions for the distribution of CY-101 and other future therapies. Details on specific new products or geographic markets to be entered have not been disclosed, but the company’s strategy emphasizes growth through innovative therapy development and geographical expansion.
Who invested in Cytovation ASA
2 investors across 2 rounds
See all investors in Cytovation ASA
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Cytovation ASA
Who invested in Cytovation ASA?
Cytovation ASA has 2 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Cytovation ASA raised?
Cytovation ASA has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Cytovation ASA last raise money?
Cytovation ASA's most recent round on record is a Series A, in Jun 2023.
What does Cytovation ASA do?
Founded in 2015 and headquartered in Bergen, Norway, Cytovation ASA focuses on creating immunotherapy products for oncology.
Where is Cytovation ASA headquartered?
Cytovation ASA is headquartered in Bergen, Norway.
Which VCs invest in companies like Cytovation ASA?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Cytovation ASA's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Cytovation ASA? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.